Ibritumomab-Tiuxetan
| Ibritumomab-Tiuxetan | ||
|---|---|---|
| Mass / length primary structure | 143.4 kDa | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| ATC code |
L01 XC10 V10 XX02 |
|
| DrugBank | BTD00069 | |
| Drug class | Monoclonal antibody | |
Ibritumomab-tiuxetan (trade name Zevalin ® ; marketing authorization holder in the EU : Bayer Schering ) is a conjugated monoclonal antibody that is used as a drug in the radioimmunotherapy of various malignant lymphomas of B cells ( lymph gland cancer ).
construction
It is an immunoconjugate , i.e. a combination of an antibody with another substance, which is formed by a stable covalent bond via thiourea between the
- monoclonal antibody ibritumomab (a recombinant, murine, monoclonal IgG1κ antibody, which is specifically directed against the B cell antigen CD20 ) and the
- Chelator (complexing agent) Tiuxetan .
Manufacturing
The antibody is produced by genetically modified Chinese hamster ovary cells ( CHO cells from Chinese Hamster Ovary ) and consists of two heavy γ chains with 445 amino acids each and two light κ chains with 213 amino acids each.
Mode of action
The chelator introduces a high affinity binding site for 90 yttrium . 90 yttrium is a β emitter . The antibody looks for the target (the B cells) and thus brings the radioactive yttrium bound to the chelator to the B cell, which exposes it directly and its immediate environment specifically and over a longer period of time to high-energy ionizing radiation , but other, spares more distant cells. In addition, the antibody alone also has a therapeutic effect (see also rituximab ). However, all cells that contain the antigen on the surface are attacked, including healthy B cells. However, B-cell precursors are spared, so that, as the hoped-for result, after the radical killing of fully developed B-cells, all cancer cells have died and the B-cells , which are essential for the defense against disease , can be regenerated from the precursors .
History
Ibritumomab tiuxetan was developed by Idec Pharmaceutical (now Biogen Idec ). It was first registered in the USA in 2002 . Ibritumomab tiuxetan was approved in the EU in 2004. The marketing authorization holder and distributor for the EU is Bayer Schering. The US company Cell Therapeutics acquired the US rights from Biogen Idec in 2007. The drug will continue to be manufactured by Biogen Idec.
literature
- German Society for Nuclear Medicine , German Society for Hematology and Oncology . Guideline for radioimmunotherapy of CD20-positive follicular B-cell non-Hodgkin lymphoma. doi : 10.3413 / nukmed-0318
Web links
- Ibritumomab-Tiuxetan pharmaceutical newspaper
- Radiation Protection Commission: Radiation protection aspects of radioimmunotherapy with Y-90-ibritumomab-tiuxetan
- Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Ibritumomab-Tiuxetan
Individual evidence
- ↑ Cell Therapeutics Inc .: press release December 27, 2007. accessed September 17, 2008.
